English Abstract
Journal Article
Add like
Add dislike
Add to saved papers

[Immunopathological complications in enteric yersiniosis: incidence and serological diagnosis (author's transl)].

Using the Widal reaction, significant titres against Yersinia enterocolitica, O-group I and V, were found in 300 of 2843 patients (10.5%) with reactive arthritis or arthralgia, and in 38 (1.3%) against Y. pseudotuberculosis type I to V. Of 510 patients with erythema nodosum 86 (16.9%) and 30 (5.9%), respectively, had significant agglutinin titres against one or the other. The results confirm the aetiological significance of Y. pseudotuberculosis, type I to V, in reactive arthritis and erythema nodosum, as well as the essential saturation of patient sera especially with Salmonella of the B or D group in the demonstration of significant antibody titres against Y. pseudotuberculosis, type II and IV. Complement-fixation tests cannot be recommended for the diagnosis of enteric Yersiniosis and its complications. Only in 201 of 554 serum samples (36.3%) with significant agglutinin titres against Y. enterocolitica O-group I and V (0 : 3 and 0 : 9 after Winblad) did the results of the Widal reaction and the microcomplement-fixation reaction agree, titres apart.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app